Download Powerpoint

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

page
1
page
2
page
3
page
4
page
5
page
6
page
7
Document related concepts
no text concepts found
Transcript 
The National Heart, Lung, and Blood Institute Pediatric
Circulatory Support Program
by J. Timothy Baldwin, Harvey S. Borovetz, Brian W. Duncan, Mark J. Gartner,
Robert K. Jarvik, and William J. Weiss
Circulation
Volume 123(11):1233-1240
March 22, 2011
Copyright © American Heart Association, Inc. All rights reserved.
The family of devices developed under the Pediatric Circulatory Support Program.
J. Timothy Baldwin et al. Circulation. 2011;123:1233-1240
Copyright © American Heart Association, Inc. All rights reserved.
Platelet activation in a lamb animal model using an earlier version of the PediaFlow ventricular
assist system after stimulation of blood with 20 μmol/L adenosine diphosphate (ADP) and 10
μmol/L platelet activating factor (PAF).
J. Timothy Baldwin et al. Circulation. 2011;123:1233-1240
Copyright © American Heart Association, Inc. All rights reserved.
Model of the PediPump in a right ventricular assist device (RVAD) configuration virtually
positioned on the diaphragmatic surface of the heart in a 3-dimensional reconstruction derived
from a computed tomography scan of an 8-month-old patient with tetralogy of Fallot.
J. Timothy Baldwin et al. Circulation. 2011;123:1233-1240
Copyright © American Heart Association, Inc. All rights reserved.
The cone bearing developed for the infant and child Jarvik 2000 ventricular assist device (VAD).
J. Timothy Baldwin et al. Circulation. 2011;123:1233-1240
Copyright © American Heart Association, Inc. All rights reserved.
An example of a flow map (A) and the corresponding wall shear rate map (B).
J. Timothy Baldwin et al. Circulation. 2011;123:1233-1240
Copyright © American Heart Association, Inc. All rights reserved.
Left, The heparin dose in the reduced-heparin thromboelastography protocol (TEG) group was
approximately one half that of the activated partial thromboplastin time (aPTT) group, and
circulating heparin (anti-factor Xa [antiXa]) was barely detectable in the TEG group.
J. Timothy Baldwin et al. Circulation. 2011;123:1233-1240
Copyright © American Heart Association, Inc. All rights reserved.
Related documents